BOT...You may well be right that delays in starting the Ph 1b Bavi + Riba combo study are related to wanting to know more results from the current repeat dose trial. Ideally, one would determine from the current repeat dose trial whether the 1mg/kg or 2 mg/kg dose level produces the best results over a 12 week period before fixing the protocol for the Bavi + Riba combo study.
IMO, it fits the logic. SK reiterated in the recent CC that Bavi was a new, innovative compound countlessly in that hour. Which leads to me to believe the FDA and PPHM have yet to establish it's development path until they achieve more data which is in progress with the mono repeat study. The mono dosing of Bavi incremently over the 2 week period satisfies both parties. I can hold out.....for a Phase Ib study with Rib, sure can, and I'll surmise it will be tested on chronic patients. I'd like to see the FDA and HCV SRB conduct a double arm study as VPHM, VRTX etx. Let's test naive and non-responders.
The chit chat about financing; charts; shorts at this juncture bore me. PPHM has plenty of money to conduct several Phase Ib studies for HCV and HIV at this juncture before it's time to consider partnering, M&A or raising funds. Financing is not an issue at this juncture IMO. Obtaining data is.....good clinical data is what makes the smallcap biotech world spin...PPHM has the assets to make that happen, will Bavi perform?
katie....
News 
Market Data 
Discover 
AI
